+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Axillary Hyperhidrosis - Pipeline Review, H1 2020

  • ID: 5017412
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 53 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Brickell Biotech Inc
  • DelNova Inc
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • Dermira Inc
  • Medytox Inc
  • MORE
Axillary Hyperhidrosis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2020, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 2 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Brickell Biotech Inc
  • DelNova Inc
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • Dermira Inc
  • Medytox Inc
  • MORE
  • Introduction
  • Report Coverage
  • Axillary Hyperhidrosis - Overview
  • Axillary Hyperhidrosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Axillary Hyperhidrosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
  • Brickell Biotech Inc
  • DelNova Inc
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • Dermira Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • Medytox Inc
  • Revance Therapeutics Inc
  • Axillary Hyperhidrosis - Drug Profiles
  • (oxybutynin + pilocarpine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DMT-410 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glycopyrrolate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glycopyrronium tosylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nivobotulinumtoxin A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • onabotulinumtoxinA biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ReViVox - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sofpironium bromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Axillary Hyperhidrosis - Dormant Projects
  • Axillary Hyperhidrosis - Discontinued Products
  • Axillary Hyperhidrosis - Product Development Milestones
  • Featured News & Press Releases
  • Mar 04, 2020: Brickell Biotech announces late-breaking oral presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for sofpironium bromide
  • Feb 20, 2020: Brickell Biotech announces publication of its U.S. phase 2b study results for Sofpironium Bromide in patients with primary axillary hyperhidrosis in the journal of the American Academy of Dermatology
  • Jan 10, 2020: Brickell Bio’s development partner, Kaken Pharmaceutical, submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
  • Jul 09, 2019: Dermata Therapeutics announces positive results from a phase 1 clinical trial of DMT410, a new topical delivery mechanism for botulinum toxin
  • Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)
  • Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis
  • Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
  • Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
  • Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
  • Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
  • Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Axillary Hyperhidrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H1 2020
  • Axillary Hyperhidrosis - Pipeline by DelNova Inc, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Dermata Therapeutics LLC, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Dermavant Sciences Inc, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Dermira Inc, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Medytox Inc, H1 2020
  • Axillary Hyperhidrosis - Pipeline by Revance Therapeutics Inc, H1 2020
  • Axillary Hyperhidrosis - Dormant Projects, H1 2020
  • Axillary Hyperhidrosis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Axillary Hyperhidrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Brickell Biotech Inc
  • DelNova Inc
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • Dermira Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • Medytox Inc
  • Revance Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll